JP2012525121A - 診断および治療のための腫瘍関連マーカーの同定 - Google Patents

診断および治療のための腫瘍関連マーカーの同定 Download PDF

Info

Publication number
JP2012525121A
JP2012525121A JP2012507624A JP2012507624A JP2012525121A JP 2012525121 A JP2012525121 A JP 2012525121A JP 2012507624 A JP2012507624 A JP 2012507624A JP 2012507624 A JP2012507624 A JP 2012507624A JP 2012525121 A JP2012525121 A JP 2012525121A
Authority
JP
Japan
Prior art keywords
nucleic acid
tumor
seq
associated antigen
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012507624A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012525121A5 (cg-RX-API-DMAC10.html
Inventor
ウグル サヒン，
エズレム テューレヒ，
ミヒャエル コスロフスキー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johannes Gutenberg-Universität Mainz
Original Assignee
Johannes Gutenberg-Universität Mainz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johannes Gutenberg-Universität Mainz filed Critical Johannes Gutenberg-Universität Mainz
Publication of JP2012525121A publication Critical patent/JP2012525121A/ja
Publication of JP2012525121A5 publication Critical patent/JP2012525121A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2012507624A 2009-04-29 2010-04-22 診断および治療のための腫瘍関連マーカーの同定 Pending JP2012525121A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17387109P 2009-04-29 2009-04-29
EP09005931A EP2249159A1 (en) 2009-04-29 2009-04-29 Identification of tumor-associated markers for diagnosis and therapy
US61/173,871 2009-04-29
EP09005931.2 2009-04-29
PCT/EP2010/002490 WO2010124812A2 (en) 2009-04-29 2010-04-22 Identification of tumor-associated markers for diagnosis and therapy

Publications (2)

Publication Number Publication Date
JP2012525121A true JP2012525121A (ja) 2012-10-22
JP2012525121A5 JP2012525121A5 (cg-RX-API-DMAC10.html) 2013-05-30

Family

ID=41100608

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012507624A Pending JP2012525121A (ja) 2009-04-29 2010-04-22 診断および治療のための腫瘍関連マーカーの同定

Country Status (6)

Country Link
US (1) US20120070430A1 (cg-RX-API-DMAC10.html)
EP (2) EP2249159A1 (cg-RX-API-DMAC10.html)
JP (1) JP2012525121A (cg-RX-API-DMAC10.html)
AU (1) AU2010243863A1 (cg-RX-API-DMAC10.html)
CA (1) CA2760395A1 (cg-RX-API-DMAC10.html)
WO (1) WO2010124812A2 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2562721A (en) * 2017-05-16 2018-11-28 Fastbase Solutions Ltd Kits, methods and their uses for detecting cell-cell interactions in a sample
WO2023244744A2 (en) * 2022-06-15 2023-12-21 Nonexomics, Inc. Compositions and methods for treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517788A (ja) * 2002-12-20 2006-08-03 ミレニアム・ファーマシューティカルズ・インコーポレイテッド １５９８６、２１８８、２０７４３、９１４８、９１５１、９７９１、４４２５２、１４１８４、４２４６１、８２０４、７９７０、２５５５２、２１６５７、２６４９２、２４１１、１５０８８、１９０５、２８８９９、６３３８０、３３９３５、１０４８０、１２６８６、２５５０１、１７６９４、１５７０１、５３０６２、４９９０８、２１６１２、３８９４９、６２１６、４６８６３、９２３５、２２０１、６９８５、９８８３、１２２３８、１８０５７、２１６１７、３９２２８、４９９２８、５４４７６、６２１１３、６４３１６、１２２６４、３２３６２、５８１９８、２８８７、３２０５、８５５７、９６００、９６９３、４４８６７、５３０５８、５５５５６、５７６５８、２２０８、１０２５２、１０３０２、１４２１８、３３８７７、１０３１７、１０４８５、２５９６４、１４８１５、１３６３、１３９７、１４８２７、２１７０８、３８０１、６４６９８、２１７９または１３２４９を使用する癌を処置するための方法および組成物
US20070231822A1 (en) * 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US20070042392A1 (en) * 2000-02-03 2007-02-22 Nuvelo, Inc. Novel nucleic acids and polypeptides
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
DE102005013846A1 (de) * 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
CN102308212A (zh) * 2008-12-04 2012-01-04 加利福尼亚大学董事会 用于确定前列腺癌诊断和预后的材料和方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517788A (ja) * 2002-12-20 2006-08-03 ミレニアム・ファーマシューティカルズ・インコーポレイテッド １５９８６、２１８８、２０７４３、９１４８、９１５１、９７９１、４４２５２、１４１８４、４２４６１、８２０４、７９７０、２５５５２、２１６５７、２６４９２、２４１１、１５０８８、１９０５、２８８９９、６３３８０、３３９３５、１０４８０、１２６８６、２５５０１、１７６９４、１５７０１、５３０６２、４９９０８、２１６１２、３８９４９、６２１６、４６８６３、９２３５、２２０１、６９８５、９８８３、１２２３８、１８０５７、２１６１７、３９２２８、４９９２８、５４４７６、６２１１３、６４３１６、１２２６４、３２３６２、５８１９８、２８８７、３２０５、８５５７、９６００、９６９３、４４８６７、５３０５８、５５５５６、５７６５８、２２０８、１０２５２、１０３０２、１４２１８、３３８７７、１０３１７、１０４８５、２５９６４、１４８１５、１３６３、１３９７、１４８２７、２１７０８、３８０１、６４６９８、２１７９または１３２４９を使用する癌を処置するための方法および組成物
US20070231822A1 (en) * 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6014037622; Ｗｏｌｆｇａｎｇ　Ｚｉｍｍｅｒｍａｎｎ，　ｅｔ　ａｌ．: Ｂｉｏｃｈｅｍｉｃａｌ　ａｎｄ　Ｂｉｏｐｈｙｓｉｃａｌ　Ｒｅｓｅａｒｃｈ　Ｃｏｍｍｕｎｉｃａｔｉｏｎｓ ＶＯＬ．１６３，　ＮＯ．３, 19890929, ＰＰ．１１９７-１２０９ *
JPN6014037625; 'Ｈｕｍａｎ　ｐｒｅｇｎａｎｃｙ-ｓｐｅｃｉｆｉｃ　ｇｌｙｃｏｐｒｏｔｅｉｎ-１ｄ　（ＰＳＧ-１ｄ）　ｍＲＮＡ，　ｃｏｍｐｌｅｔｅ　ｃｄｓ．' ＧｅｎＢａｎｋ , 19930427, ＡＣＣＥＳＳＩＯＮ　Ｎｏ．Ｍ３３６６３ *

Also Published As

Publication number Publication date
US20120070430A1 (en) 2012-03-22
WO2010124812A2 (en) 2010-11-04
EP2249159A1 (en) 2010-11-10
EP2425252A2 (en) 2012-03-07
AU2010243863A1 (en) 2011-11-03
CA2760395A1 (en) 2010-11-04
WO2010124812A3 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
JP6285472B2 (ja) 診断及び治療のための腫瘍関連マーカーの同定
JP6196338B2 (ja) 診断および治療のための腫瘍関連抗原の同定
JP5809067B2 (ja) 癌の診断および治療のための方法および組成物
JP5731436B2 (ja) 腫瘍診断と治療のための表面関連抗原の同定
US20120070430A1 (en) Identification of tumor-associated markers for diagnosis and therapy
AU2017208276B2 (en) Identification of tumor-associated markers for diagnosis and therapy
AU2014202125B2 (en) Identification of tumor-associated markers for diagnosis and therapy
MX2008003464A (en) Identification of tumor-associated antigens for diagnosis and therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140902

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150331